Your browser is no longer supported. Please, upgrade your browser.
NBIX Neurocrine Biosciences, Inc. daily Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E68.63 EPS (ttm)1.84 Insider Own0.90% Shs Outstand92.60M Perf Week-1.24%
Market Cap11.88B Forward P/E25.84 EPS next Y4.88 Insider Trans-24.79% Shs Float88.71M Perf Month11.42%
Income176.50M PEG- EPS next Q0.81 Inst Own99.05% Short Float5.44% Perf Quarter31.40%
Sales886.80M P/S13.39 EPS this Y74.70% Inst Trans0.33% Short Ratio5.57 Perf Half Y12.09%
Book/sh7.56 P/B16.68 EPS next Y64.70% ROA14.40% Target Price128.65 Perf Year47.12%
Cash/sh8.19 P/C15.39 EPS next 5Y- ROE29.50% 52W Range72.14 - 136.26 Perf YTD17.29%
Dividend- P/FCF40.87 EPS past 5Y19.90% ROI6.00% 52W High-7.47% Beta1.34
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin99.10% 52W Low74.77% ATR4.54
Employees700 Current Ratio6.90 Sales Q/Q71.30% Oper. Margin26.20% RSI (14)52.95 Volatility3.84% 3.59%
OptionableYes Debt/Eq0.00 EPS Q/Q134.40% Profit Margin19.90% Rel Volume1.07 Prev Close129.69
ShortableYes LT Debt/Eq0.59 EarningsMay 06 AMC Payout0.00% Avg Volume866.68K Price126.08
Recom1.90 SMA200.74% SMA505.84% SMA20020.10% Volume927,590 Change-2.78%
Jun-29-20Downgrade Goldman Buy → Neutral $135
Jun-09-20Initiated Wedbush Outperform $147
Mar-06-20Initiated Citigroup Buy $124
Feb-27-20Initiated Barclays Equal Weight $105
Feb-24-20Initiated William Blair Outperform
Feb-06-20Initiated Mizuho Neutral
Feb-05-20Reiterated H.C. Wainwright Buy $102 → $125
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $110
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jul-16-19Initiated Oppenheimer Outperform $100
Jun-05-19Initiated Guggenheim Neutral
May-21-19Initiated Credit Suisse Outperform $95
Apr-22-19Upgrade JP Morgan Neutral → Overweight
Apr-12-19Initiated Evercore ISI Outperform
Feb-06-19Reiterated BofA/Merrill Buy $124 → $117
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-13-18Initiated Goldman Buy $103
Nov-21-18Initiated Canaccord Genuity Buy $111
Sep-10-18Initiated Morgan Stanley Overweight $145
Aug-07-18Initiated Stifel Buy $137
Jul-13-20 07:16PM  
04:01PM  
Jul-01-20 07:00AM  
Jun-25-20 12:17PM  
Jun-17-20 04:04PM  
Jun-16-20 07:00AM  
Jun-15-20 04:01PM  
Jun-08-20 11:01AM  
Jun-05-20 11:26AM  
Jun-04-20 04:01PM  
Jun-03-20 01:44AM  
Jun-01-20 11:46AM  
May-29-20 04:13PM  
May-26-20 04:01PM  
09:39AM  
May-23-20 08:00AM  
May-18-20 12:16PM  
May-14-20 07:29PM  
06:27AM  
May-13-20 04:01PM  
02:58PM  
02:38PM  
May-12-20 04:55PM  
May-11-20 04:01PM  
May-07-20 08:09PM  
05:30PM  
04:01PM  
May-06-20 05:35PM  
04:01PM  
May-05-20 04:01PM  
08:35AM  
Apr-29-20 12:34PM  
Apr-27-20 11:07AM  
10:24AM  
07:39AM  
07:30AM  
Apr-24-20 11:41AM  
Apr-20-20 01:31PM  
Apr-15-20 04:01PM  
Apr-03-20 08:30AM  
Mar-30-20 06:06PM  
Mar-27-20 12:45PM  
Mar-26-20 11:40AM  
Mar-18-20 02:29PM  
Mar-14-20 10:59AM  
Mar-11-20 08:53PM  
02:45PM  
Mar-10-20 11:40AM  
Mar-05-20 02:38PM  
Feb-25-20 04:01PM  
Feb-19-20 12:08PM  
Feb-15-20 07:37AM  
Feb-07-20 09:28AM  
Feb-05-20 09:35AM  
Feb-04-20 05:55PM  
04:01PM  
07:51AM  
Feb-03-20 05:00PM  
08:33AM  
Feb-02-20 01:04PM  
Jan-31-20 09:15AM  
07:48AM  
07:16AM  
Jan-28-20 12:31PM  
Jan-20-20 04:30PM  
10:02AM  
Jan-17-20 08:22AM  
Jan-13-20 08:30AM  
Jan-12-20 06:30PM  
Jan-10-20 11:40AM  
01:00AM  
Jan-09-20 12:10PM  
Jan-06-20 04:01PM  
10:31AM  
Dec-25-19 03:12PM  
Dec-23-19 07:06PM  
01:01AM  
Dec-19-19 07:05AM  
Dec-07-19 08:45AM  
Dec-06-19 11:11AM  
Dec-03-19 07:59AM  
Dec-02-19 07:30AM  
Nov-27-19 06:52AM  
Nov-26-19 11:54PM  
Nov-12-19 04:01PM  
Nov-10-19 12:50AM  
Nov-05-19 04:01PM  
Nov-04-19 07:15PM  
04:01PM  
01:38PM  
Nov-01-19 08:53AM  
Oct-28-19 10:32AM  
09:30AM  
Oct-22-19 03:56PM  
Oct-15-19 10:10AM  
Oct-14-19 04:59PM  
04:01PM  
09:15AM  
Oct-10-19 09:30AM  
Oct-04-19 06:00PM  
Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lippoldt DarinChief Legal OfficerJul 09Option Exercise35.991,65759,63527,678Jul 10 04:26 PM
Lippoldt DarinChief Legal OfficerJul 09Sale136.021,657225,38626,021Jul 10 04:26 PM
Lippoldt DarinChief Legal OfficerJun 23Option Exercise32.995,000164,95031,021Jun 25 04:15 PM
ROBERTS EIRYChief Medical OfficerJun 23Option Exercise77.815,000389,05014,416Jun 25 04:19 PM
ROBERTS EIRYChief Medical OfficerJun 23Sale130.005,000650,0009,416Jun 25 04:19 PM
Lippoldt DarinChief Legal OfficerJun 23Sale130.005,000650,00026,021Jun 25 04:15 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 11Option Exercise35.905,571199,97677,563Jun 15 05:31 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 19Option Exercise35.9910,000359,900114,741May 20 06:59 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 19Sale126.5542,7495,409,93371,992May 20 06:59 PM
Lippoldt DarinChief Legal OfficerMay 18Option Exercise32.995,000164,95031,021May 20 07:15 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 18Option Exercise35.9910,000359,900114,741May 20 06:59 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 18Sale119.9810,0001,199,800104,741May 20 06:59 PM
Lippoldt DarinChief Legal OfficerMay 18Sale120.005,000600,00026,021May 20 07:15 PM
Bozigian Haig P.Chief Development OfficerMay 12Option Exercise63.1061,5553,884,054167,204May 14 08:09 PM
Bozigian Haig P.Chief Development OfficerMay 12Sale114.9461,5557,075,396148,633May 14 08:09 PM
ABERNETHY MATTChief Financial OfficerMay 07Option Exercise73.6015,0001,104,00020,953May 11 08:17 PM
ABERNETHY MATTChief Financial OfficerMay 07Sale110.2115,0001,653,1345,953May 11 08:17 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 07Sale105.448,682915,454104,741May 11 08:06 PM
SHERWIN STEPHEN ADirectorApr 28Sale99.3917,6871,757,96629,861Apr 30 04:27 PM
ABERNETHY MATTChief Financial OfficerApr 28Sale102.491,741178,4355,953Apr 30 04:25 PM
GORMAN KEVIN CHARLESChief Executive OfficerApr 24Sale99.452,906289,016434,971Apr 28 08:41 PM
Gano KyleChief Business Development OffApr 24Sale99.471,934192,37793,967Apr 28 08:40 PM
Cooke JulieChief Human Resources OfficerApr 24Sale99.461,934192,3646,631Apr 28 08:38 PM
Bozigian Haig P.Chief Development OfficerApr 24Sale99.461,934192,351148,633Apr 28 08:35 PM
BENEVICH ERICChief Commercial OfficerApr 24Sale99.451,934192,33813,344Apr 28 08:33 PM
ABERNETHY MATTChief Financial OfficerApr 24Sale99.521,934192,4677,694Apr 28 08:32 PM
ROBERTS EIRYChief Medical OfficerApr 24Sale99.471,934192,3769,416Apr 28 08:46 PM
Lloyd-Smith MalcolmChief Regulatory OfficerApr 24Sale99.451,934192,32924,941Apr 28 08:44 PM
Lippoldt DarinChief Legal OfficerApr 24Sale99.491,934192,41626,021Apr 28 08:43 PM
Grigoriadis Dimitri E.Chief Research OfficerApr 24Sale99.411,934192,258113,423Apr 28 08:42 PM
BENEVICH ERICChief Commercial OfficerApr 15Sale94.658,632817,01811,603Apr 17 09:48 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Option Exercise59.6628,9691,728,14739,127Feb 11 07:21 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Sale104.5628,9693,029,08623,200Feb 11 07:21 PM
ROBERTS EIRYChief Medical OfficerFeb 07Sale103.311,623167,6757,452Feb 11 07:23 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 07Sale103.281,015104,82723,200Feb 11 07:21 PM
Lippoldt DarinChief Legal OfficerFeb 07Sale103.321,522157,24724,124Feb 11 07:17 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 07Sale103.311,218125,833111,682Feb 11 07:16 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 07Sale103.353,248335,696432,357Feb 11 07:14 PM
Gano KyleChief Business Development OffFeb 07Sale103.331,623167,71091,975Feb 11 07:13 PM
Cooke JulieChief Human Resources OfficerFeb 07Sale103.2691394,2764,643Feb 11 07:10 PM
Bozigian Haig P.Chief Development OfficerFeb 07Sale103.331,623167,702146,641Feb 11 07:09 PM
BENEVICH ERICChief Commercial OfficerFeb 07Sale103.322,030209,74720,087Feb 11 07:08 PM
ABERNETHY MATTChief Financial OfficerFeb 07Sale103.352,030209,8075,701Feb 11 07:06 PM
Gano KyleChief Business Development OffFeb 06Sale101.411,000101,41390,514Feb 07 06:54 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 06Sale101.4480381,456110,587Feb 07 06:50 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 06Sale101.521,490151,25822,287Feb 07 06:47 PM
Lippoldt DarinChief Legal OfficerFeb 06Sale101.471,198121,55622,755Feb 07 06:46 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale101.564,343441,068429,436Feb 07 06:44 PM
Bozigian Haig P.Chief Development OfficerFeb 06Sale101.561,395141,670145,180Feb 07 06:37 PM
BENEVICH ERICChief Commercial OfficerFeb 06Sale101.481,395141,56118,262Feb 07 06:35 PM
Gano KyleChief Business Development OffFeb 05Sale103.053,690380,26287,204Feb 07 06:54 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale103.151,618166,894109,320Feb 07 06:50 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale103.051,948200,73320,455Feb 07 06:47 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale102.981,750180,20721,133Feb 07 06:46 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale103.095,449561,726423,351Feb 07 06:44 PM
Cooke JulieChief Human Resources OfficerFeb 05Sale103.1760562,4173,821Feb 07 06:38 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale103.022,046210,779143,292Feb 07 06:37 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale103.031,954201,31116,279Feb 07 06:35 PM
ROBERTS EIRYChief Medical OfficerJan 08Sale111.112,632292,4455,991Jan 10 04:10 PM
ABERNETHY MATTChief Financial OfficerDec 02Sale116.331,645191,3603,876Dec 04 06:06 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 18Option Exercise35.995,000179,950113,408Nov 19 05:37 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 18Sale115.985,000579,900108,408Nov 19 05:37 PM
Lippoldt DarinChief Legal OfficerNov 08Option Exercise32.9910,000329,90026,728Nov 13 04:36 PM
LYONS GARY ADirectorNov 08Sale110.005,000550,000225,697Nov 13 04:41 PM
Lippoldt DarinChief Legal OfficerNov 08Sale110.0110,0001,100,05720,103Nov 13 04:36 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 01Option Exercise32.9910,188336,102118,596Nov 05 04:37 PM
LYONS GARY ADirectorNov 01Sale100.225,000501,104230,697Nov 05 04:38 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 01Sale100.3410,1881,022,298108,408Nov 05 04:37 PM
Lloyd-Smith MalcolmChief Regulatory OfficerOct 14Option Exercise15.459,956153,82029,569Oct 16 04:20 PM
Lloyd-Smith MalcolmChief Regulatory OfficerOct 14Sale90.859,956904,48719,613Oct 16 04:20 PM
Cooke JulieChief Human Resources OfficerOct 02Sale88.5698787,4093,276Oct 04 06:15 PM
Lippoldt DarinChief Legal OfficerSep 03Option Exercise32.996,736222,22126,839Sep 05 04:09 PM
Lippoldt DarinChief Legal OfficerSep 03Sale100.006,736673,60020,103Sep 05 04:09 PM
Lippoldt DarinChief Legal OfficerAug 27Option Exercise32.991,60052,78421,561Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 27Sale100.001,600160,00019,961Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 23Option Exercise32.991,66454,89521,625Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 23Sale100.091,664166,55519,961Aug 27 07:52 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 09Option Exercise32.993,03199,993420,628Aug 13 04:44 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Option Exercise8.6626,330228,018443,927Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Sale95.6426,3302,518,154417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Option Exercise8.662,75923,893420,356Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Sale95.122,759262,440417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Option Exercise8.6650,911440,889468,508Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Sale95.1550,9114,844,380417,597Aug 08 07:39 PM
Bozigian Haig P.Chief Development OfficerJul 30Option Exercise38.9144,3561,725,704167,576Jul 31 07:11 PM
Grigoriadis Dimitri E.Chief Research OfficerJul 30Option Exercise32.9950,0001,649,500168,408Jul 31 07:12 PM
Lippoldt DarinChief Legal OfficerJul 30Option Exercise18.1515,831287,33335,792Jul 31 07:14 PM
LYONS GARY ADirectorJul 30Sale92.0710,000920,686235,697Jul 31 07:15 PM
Lippoldt DarinChief Legal OfficerJul 30Sale92.1315,8311,458,56919,961Jul 31 07:14 PM
Grigoriadis Dimitri E.Chief Research OfficerJul 30Sale92.9260,0005,575,438108,408Jul 31 07:12 PM
Bozigian Haig P.Chief Development OfficerJul 30Sale92.7744,3564,114,858141,976Jul 31 07:11 PM
Bozigian Haig P.Chief Development OfficerJul 15Option Exercise32.9930,6801,012,133172,656Jul 17 07:08 PM
Bozigian Haig P.Chief Development OfficerJul 15Sale87.5030,6802,684,506141,976Jul 17 07:08 PM
BENEVICH ERICChief Commercial OfficerJul 15Sale87.445,835510,20114,910Jul 17 07:06 PM